Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial.

MLA

Engstrøm, Thomas, et al. “Complete Revascularisation versus Treatment of the Culprit Lesion Only in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease (DANAMI-3—PRIMULTI): An Open-Label, Randomised Controlled Trial.” Lancet (London, England), vol. 386, no. 9994, Aug. 2015, pp. 665–71. EBSCOhost, https://doi.org/10.1016/s0140-6736(15)60648-1.

APA

Engstrøm, T., Kelbæk, H., Helqvist, S., Høfsten, D. E., Kløvgaard, L., Holmvang, L., Jørgensen, E., Pedersen, F., Saunamäki, K., Clemmensen, P., De Backer, O., Ravkilde, J., Tilsted, H.-H., Villadsen, A. B., Aarøe, J., Jensen, S. E., Raungaard, B., & Køber, L. (2015). Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet (London, England), 386(9994), 665–671. https://doi.org/10.1016/s0140-6736(15)60648-1

Chicago

Engstrøm, Thomas, Henning Kelbæk, Steffen Helqvist, Dan Eik Høfsten, Lene Kløvgaard, Lene Holmvang, Erik Jørgensen, et al. 2015. “Complete Revascularisation versus Treatment of the Culprit Lesion Only in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease (DANAMI-3—PRIMULTI): An Open-Label, Randomised Controlled Trial.” Lancet (London, England) 386 (9994): 665–71. doi:10.1016/s0140-6736(15)60648-1.